#ScienceSaturday 🧬 What if we could help the immune system’s cancer-fighting T cells regain their ability to attack tumors, even after they become exhausted? 🔬 New research published in Nature identifies a potential way to do just that. Scientists found that targeting a protein called ZMYND8 can restore signaling pathways that help CD8+ T cells maintain their cancer-killing abilities, rather than progressing toward a more dysfunctional state. 🛡️ Why does this matter? T-cell exhaustion is a major challenge in cancer #immunotherapy. When T cells are exposed to persistent signals from cancer cells, they can gradually lose their ability to mount an effective attack. Researchers found that removing ZMYND8’s inhibitory influence strengthened IL-2 signaling, which helps support T-cell activity and function. 💡 The findings are especially promising because targeting ZMYND8 enhanced antitumor activity in preclinical models, particularly when combined with IL-2 therapy or immune checkpoint blockade. The researchers also observed improvements in human T cells in laboratory studies, offering insight into the potential relevance of this approach. 🚀 Although more research is needed before this strategy can be translated into patient care, the study offers a new avenue for investigating how we might strengthen the immune system’s response to #cancer. 📖 Read the full study in Nature: nature.com/articles/s41586-0… @hongbo_chi @StJudeResearch @StJude